TLDR: Insilico Medicine’s founder and CEO, Alex Zhavoronkov, and President, Alex Aliper, are slated to speak at the 9th Future Investment Initiative (FII9) in Riyadh from October 27-30, 2025. They will highlight how generative AI is revolutionizing drug discovery and healthcare, demonstrating significant efficiency gains with their Pharma.AI platform.
Riyadh, Saudi Arabia – The 9th edition of the Future Investment Initiative (FII9), themed ‘The Key to Prosperity,’ is set to host over 600 distinguished speakers and 20 confirmed Heads of State from October 27-30, 2025, at the King Abdulaziz International Conference Center. Among the prominent voices shaping discussions on global growth, AI responsibility, and innovation will be the leadership team from Insilico Medicine, a global AI-driven biotech company.
Alex Zhavoronkov PhD, founder and CEO of Insilico Medicine, will deliver a keynote address on October 29, from 1:45 PM-2:10 PM local time. His presentation, titled ‘Can Cell-Based Innovation Keep Humanity in Peak Condition?‘, will delve into how generative AI breakthroughs are driving real-world healthcare solutions. The following day, Alex Aliper PhD, President of Insilico Medicine, will participate in the FII Innovators Pitch 2025 session. She will share insights gained from Insilico’s continuous AI platform development and the reproducible proof-of-concept achieved through their highly efficient novel pipelines.
Insilico Medicine is at the forefront of leveraging its proprietary Pharma.AI platform and advanced automated laboratories to accelerate drug discovery. The company has demonstrated a significant boost in efficiency compared to traditional drug discovery methods, which often require 2.5-4 years. Recent key timeline benchmarks for internal Drug Candidate (DC) programs from 2021 to 2024 show an average time to DC of just 12-18 months, with 60-200 molecules synthesized and tested per program. This integration of AI and automation technologies, combined with deep in-house drug discovery capabilities, enables Insilico to deliver innovative drug solutions for unmet medical needs across various therapeutic areas, including fibrosis, oncology, immunology, pain, obesity, and metabolic disorders.
Also Read:
- Expedition Medicines Launched by Flagship Pioneering with $50M to Revolutionize Small Molecule Drug Discovery Using Generative AI
- AI’s Transformative Impact: The Top Trends of 2025 Reshaping Daily Life
The FII9 conference will explore urgent topics such as global growth, AI and technology responsibility, and the next generation of talent, fostering communication between global investors, visionary leaders, and pioneering minds. Insilico Medicine’s contributions underscore the critical role of artificial intelligence in driving future growth and transforming the healthcare landscape.
